Dr Giang Le, Professor Jonathan Baell, Dr Luigi Aurelio,
Dr Romke Bron, Dr Simona Carbone, Professor Nigel Bunnet,
Dr Nicholas Veldhuis, Dr Bim Graham, Dr Laura Edginton-Mitchell,
Josh Conner, Dr Daniel Poole
Professor Nigel Bunnett (Deputy Director, MIPS),
who together with Dr Daniel Poole, also from MIPS,
will lead the initial three-year research program,
said gastrointestinal diseases are a major cause
of human suffering.
“There is no cure for many gastrointestinal diseases
and current treatments are either inadequate or
have major sideeffects. If we can understand the
mechanisms that trigger these diseases we can
go on to develop effective drugs to treat them,”
Professor Bunnett said.
“Monash possesses the expertise, technology
and materials at its research facilities necessary
to conduct drug discovery, research and preclinical
pharmaceutical development activities into
gastrointestinal diseases.”
Professor Bunnett said the research program will
build on work by MIPS to better understand the
causes of disorders of gastrointestinal function
and sensation and could potentially lead to powerful
therapies for digestive and sensory diseases.
“A major thrust of the work will be to make use
of our expertise in nano-medicine to deliver drugs
to the source of disease within the body,” he said.
Dr Tetsuyuki Maruyama, is the General Manager
of the Pharmaceutical Research Division at Takeda,
said the alliance was the